MOMELOTINIB DIHYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for momelotinib dihydrochloride and what is the scope of patent protection?
Momelotinib dihydrochloride
is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Momelotinib dihydrochloride has eighty-nine patent family members in thirty-five countries.
One supplier is listed for this compound.
Summary for MOMELOTINIB DIHYDROCHLORIDE
International Patents: | 89 |
US Patents: | 3 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 18 |
Clinical Trials: | 16 |
Patent Applications: | 20 |
DailyMed Link: | MOMELOTINIB DIHYDROCHLORIDE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for MOMELOTINIB DIHYDROCHLORIDE
Generic Entry Date for MOMELOTINIB DIHYDROCHLORIDE*:
Constraining patent/regulatory exclusivity:
TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF OR SECONDARY MF [POST-POLYCYTHEMIA VERA (PV) AND POST-ESSENTIAL THROMBOCYTHEMIA (ET)], IN ADULTS WITH ANEMIA Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for MOMELOTINIB DIHYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Covance | Phase 3 |
CTI BioPharma | Phase 3 |
PSI CRO | Phase 3 |
US Patents and Regulatory Information for MOMELOTINIB DIHYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-003 | Sep 15, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-003 | Sep 15, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-002 | Sep 15, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MOMELOTINIB DIHYDROCHLORIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Cyprus | 1117180 | ⤷ Try a Trial | |
Croatia | P20201492 | ⤷ Try a Trial | |
Japan | 2023021454 | N-(シアノメチル)-4-(2-(4-モルホリノフェニルアミノ)ピリミジン-4-イル)ベンズアミド塩酸塩 | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |